Compare · QSI vs TMO
QSI vs TMO
Side-by-side comparison of Quantum-Si Incorporated (QSI) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both QSI and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $217.52B, about 1350.2x QSI ($161.1M).
- Over the past year, QSI is down 32.7% and TMO is up 20.2% - TMO leads by 52.9 points.
- TMO has been more active in the news (11 items in the past 4 weeks vs 5 for QSI).
- TMO has more recent analyst coverage (25 ratings vs 4 for QSI).
- Company
- Quantum-Si Incorporated
- Thermo Fisher Scientific Inc
- Price
- $0.74-6.29%
- $588.00-1.29%
- Market cap
- $161.1M
- $217.52B
- 1M return
- -9.25%
- +8.23%
- 1Y return
- -32.72%
- +20.18%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 5
- 11
- Recent ratings
- 4
- 25
Quantum-Si Incorporated
Quantum-Si incorporated operates first next-generation protein sequencing and genomics platform for healthcare industries. It offers a single molecule detection solution to decode the molecules of life, including sample preparation, single molecule, massively parallel, and protein identification. The company's technology has the applications in proteomics, single cell, transcriptomics, genomics, metabolomics, and drug testing and screening fields. The company is based in Guilford, Connecticut. Quantum-Si incorporated is a subsidiary of 4Catalyzer Corporation.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest QSI
- SEC Form 10-Q filed by Quantum-Si Incorporated
- Quantum-Si Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update
- Quantum-Si to Report Second Quarter 2026 Financial Results on August 13, 2026
- Quantum-Si Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- GC & Corp. Secretary Lapointe Christian sold $14,469 worth of shares (15,588 units at $0.93), decreasing direct ownership by 1% to 1,182,429 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Keyes Jeffry R. sold $7,642 worth of shares (8,233 units at $0.93), decreasing direct ownership by 0.48% to 1,724,349 units (SEC Form 4) (tax withholding)
- Chief Product Officer Vieceli John S. sold $28,053 worth of shares (30,223 units at $0.93), decreasing direct ownership by 3% to 1,140,434 units (SEC Form 4) (withholding obligation)
- President & CEO Hawkins Jeffrey Alan sold $20,997 worth of shares (22,621 units at $0.93), decreasing direct ownership by 0.61% to 3,669,802 units (SEC Form 4) (for tax liability)
- SEC Form 144 filed by Quantum-Si Incorporated
Latest TMO
- Executive Vice President Shafer Michael D exercised 25,500 shares at a strike of $370.58 and sold $15,300,000 worth of shares (25,500 units at $600.00) as part of a pre-agreed trading plan (SEC Form 4)
- Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg
- VP & Chief Accounting Officer Holmes Joseph R. exercised 420 shares at a strike of $309.63 and sold $245,620 worth of shares (420 units at $584.81) (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 275 shares at a strike of $309.63 and sold $2,862,002 worth of shares (4,883 units at $586.12) as part of a pre-agreed trading plan (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. exercised 5,850 shares at a strike of $309.63 and sold $3,393,000 worth of shares (5,850 units at $580.00), decreasing direct ownership by 0.00% to 14,784 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,616,967 worth of shares (15,000 units at $574.46) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,628,434 worth of shares (15,000 units at $575.23) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- SEC Form 10-Q filed by Thermo Fisher Scientific Inc
- President & COO Pettiti Gianluca sold $226,000 worth of shares (400 units at $565.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 24,651 units (SEC Form 4)
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits